Autoimmune Disease Treatment Companies

Immunovant (IMVT) Soared nearly 100% after Phase 1 trial results of their injectable treatment, IMVT-1402, showed successful reduction in disease-causing antibodies. Phase 2 trials are planned for 2024.

AstraZeneca Announced positive Phase 3 data for their anti-IL-17A drug, brodalumab, showing significant improvement in psoriatic arthritis symptoms compared to placebo. Regulatory submissions are planned for 2024.

Eli Lilly Reported positive Phase 2b data for their JAK inhibitor, abrocitinib, in treating ulcerative colitis. They plan to initiate Phase 3 trials in 2024.

Pfizer Acquired Viavi Pharmaceuticals for $5.2 billion, gaining access to Viavi's late-stage lupus drug, atacicept. This strengthens Pfizer's autoimmune disease portfolio.

Roche and Gilead Formed a research collaboration to develop new treatments for inflammatory bowel disease. This combines expertise and resources to accelerate discoveries.

Sanofi and Kymab Partnered to develop and commercialize anti-inflammatory antibodies targeting IL-17C and IL-17A for various autoimmune diseases.

List of Autoimmune Disease Treatment Key Companies in the Market

• Abbott Laboratories

• Amgen Inc.

• Genentech Inc.

• Bayer Schering Pharma AG

• Biogen Idec Inc.

• Bio-Rad

• Chugai Pharmaceutical Co. Ltd.

• Danaher

• Elan Corporation Plc

• Eli Lilly and Company

• F. Hoffmann-La Roche AG

• GlaxoSmithKline Plc

• HYCOR Biomedical

• Johnson & Johnson Inc.

• Merck & Co. Inc.